TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9282969

Group type: EXPERIMENTAL
Intervention: Cholestyramine (6 g/h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study: 8332150

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 486

Group type: COMPARATOR
Intervention: Other antiarrhythmic drugs combined
Number of subjects: 486
Study: 31387766

Group type: EXPERIMENTAL
Intervention: Firearm safety message only (n = 115)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Firearm safety and mental health promotion messages (n = 133)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Active control group exposed to mental health promotion message only (n = 110)
Number of subjects: 358
Study: 29225161

Group type: EXPERIMENTAL
Intervention: General Self-Efficacy (GSE) scale assessment
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: General Self-Efficacy (GSE) scale assessment with interaction terms
Number of subjects: 456
Study: 26983642

Group type: EXPERIMENTAL
Intervention: Oral PSORI-CM01 plus topical sequential therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo plus topical sequential therapy
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral PSORI-CM01
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 23759828

Group type: EXPERIMENTAL
Intervention: PRECEDE-PROCEED educational program
Number of subjects: 0
Study: 22490715

Group type: EXPERIMENTAL
Intervention: CSWT (shots/spot at 0.09 mJ/mm(2) for 9 spots, 9 times within 3 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 20469954

Group type: EXPERIMENTAL
Intervention: Screening and educational intervention (SI)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Control intervention (CIN)
Number of subjects: 421
Study: 17892610

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine (0.5%) + ketamine (0.1 mg kg‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine (0.5%) + ketamine (0.1 mg kg‐1) + midazolam (0.02 mg kg‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine (0.5%)
Number of subjects: 60
Study: 15950180

Group type: EXPERIMENTAL
Intervention: Anti-citrullinated huCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control sera
Number of subjects: 0
Study: 12364444

Group type: EXPERIMENTAL
Intervention: Canrenoate (200 mg as an iv bolus, followed by 200 mg infused in 250 ml saline)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.02 mg/kg, orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 10469814

Group type: EXPERIMENTAL
Intervention: Amethocaine gel (1 g for 30 minutes)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lidocaine-prilocaine cream (1 g for 60 minutes)
Number of subjects: 39
Study: 8729705

Group type: EXPERIMENTAL
Intervention: Hypnosis intervention (two sessions of 45 minutes each)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (no hypnosis)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 2000
Study: 1808626

Group type: EXPERIMENTAL
Intervention: 30 mg aspirin daily
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: 1000 mg aspirin daily
Number of subjects: 701
Study: 6351586

Group type: EXPERIMENTAL
Intervention: Chromium supplementation (200 micrograms trivalent chromium daily for 6 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30541041

Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid (triamcinolone 20 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: IA saline
Number of subjects: 56
Study: 28355372

Group type: EXPERIMENTAL
Intervention: Patent blue (group A)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Methylene blue (group B)
Number of subjects: 142
Study: 26135553

Group type: COMPARATOR
Intervention: Single Session Counseling (SSC)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MINT)-TLC
Number of subjects: 194
Study: 23401275

Group type: EXPERIMENTAL
Intervention: Azithromycin combined with prednisolone (treatment group, n = 28)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Azithromycin alone (control group, n = 30)
Number of subjects: 58
Study: 22946986

Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 170

Group type: COMPARATOR
Intervention: MMF
Number of subjects: 170
Study: 19388505

Group type: EXPERIMENTAL
Intervention: Preoperative fluid bolus (up to 1,000 mL using the 4‐2‐1 formula)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Routine replacement fluids (control group)
Number of subjects: 46
Study: 17451562

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 15164862

Group type: EXPERIMENTAL
Intervention: Oppositional behavior in male child actor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior associated with ADHD in male child actor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oppositional behavior in female child actor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior associated with ADHD in female child actor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control tape (unremarkable behavior)
Number of subjects: 0
Study: 11167354

Group type: EXPERIMENTAL
Intervention: Drug therapy plus training on the use of nasal spray (Group B)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Drug therapy plus training on the use of nasal spray and a lesson on rhinitis and asthma (Group C)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Drug therapy alone (Group A)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Trained groups (Group B and C)
Number of subjects: 101
Study: 9554567

Group type: EXPERIMENTAL
Intervention: rhIGF‐1 (80 µg/kg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: rhIGF‐1 (80 µg/kg/day) + rhGH (50 µg/kg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 8
Study: 7802322

Group type: EXPERIMENTAL
Intervention: Buccal prosidol tablets
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Prosidol for postoperative analgesia
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Prosidol as a component of total anesthesia
Number of subjects: 113
Study: 3197580

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg intravenous bolus injection)
Number of subjects: 7
Study: 31357997

Group type: EXPERIMENTAL
Intervention: Mass Testing and Treatment (MTaT) delivered by community health volunteers (CHVs) three times a year for 2 years
Number of subjects: 90000

Group type: EXPERIMENTAL
Intervention: Community engagement and capacity building efforts
Number of subjects: 90000

Group type: EXPERIMENTAL
Intervention: Training of more than 80 Kenya MOH CHVs and other staff
Number of subjects: 90000
Study: 28077091

Group type: EXPERIMENTAL
Intervention: Transradial approach
Number of subjects: 400

Group type: COMPARATOR
Intervention: Transfemoral approach
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 400
Study: 25903751

Group type: EXPERIMENTAL
Intervention: Cloth masks
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Medical masks
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Control (usual practice)
Number of subjects: 1607
Study: 23562254

Group type: EXPERIMENTAL
Intervention: Intraarticular drainage for 48 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraarticular drainage for 24 hours
Number of subjects: 0
Study: 21761706

Group type: EXPERIMENTAL
Intervention: Sublingual administration of allergen (SLIT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nasal spray of budesonide (Control)
Number of subjects: 52
Study: 19258920

Group type: EXPERIMENTAL
Intervention: Motavizumab 15 mg/kg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Motavizumab
Number of subjects: 217

Group type: COMPARATOR
Intervention: Palivizumab 15 mg/kg
Number of subjects: 217
Study: 16961676

Group type: EXPERIMENTAL
Intervention: Drug only (orlistat)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Drug + brief counselling
Number of subjects: 250

Group type: COMPARATOR
Intervention: Brief counselling only
Number of subjects: 250
Study: 15532817

Group type: EXPERIMENTAL
Intervention: Cimetidine administered at an early stage after bowel surgery while receiving parenteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11683207

Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa) alone or in combination with growth hormone (GH) for 3 years
Number of subjects: 30
Study: 9804577

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP; 1.8 g . kg‐1 . day‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-protein diet (LP; 0.7 g . kg‐1 . day‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 16
Study: 7933348

Group type: EXPERIMENTAL
Intervention: Penicillin V (500 mg twice a day)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 3415422

Group type: EXPERIMENTAL
Intervention: Standard dose of fluphenazine decanoate (average, 25 mg every two weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Minimal dose of fluphenazine decanoate (average, 3.8 mg every two weeks)
Number of subjects: 70
Study: 30768663

Group type: EXPERIMENTAL
Intervention: Internal hex and convergent transmucosal collar implants
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Supracrestally placed implants
Number of subjects: 61
Study: 29941500

Group type: EXPERIMENTAL
Intervention: Insulin glargine followed by metformin for 3 months and then metformin for 9 months
Number of subjects: 91

Group type: COMPARATOR
Intervention: Metformin alone for 12 months
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Insulin glargine followed by metformin
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 91
Study: 27106241

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT)
Number of subjects: 81
Study: 24345601

Group type: EXPERIMENTAL
Intervention: 12-week web-based physical activity intervention
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 397
Study: 22931173

Group type: EXPERIMENTAL
Intervention: Model vehicle demonstrating risky behavior (running a yellow light)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model vehicle demonstrating safe behavior (stopping at the intersection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model vehicle demonstrating safe and risky behaviors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model vehicle demonstrating safe behavior
Number of subjects: 0
Study: 20700680

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (non-stimulating catheter insertion)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stimulating catheter technique (electrical stimulation)
Number of subjects: 80
Study: 17693905

Group type: EXPERIMENTAL
Intervention: Inhaled steroid, Budesonide (0.25 mg/2 mL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inhaled placebo (2 mL of inhaled 0.9% saline)
Number of subjects: 32
Study: 15856454

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 117

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 117
Study: 12040440

Group type: EXPERIMENTAL
Intervention: BFM-oriented therapy without cranial irradiation
Number of subjects: 467

Group type: COMPARATOR
Intervention: High doses of L-asparaginase (HD-L-ASP) during maintenance treatment
Number of subjects: 467

Group type: COMPARATOR
Intervention: High doses of intravenous 6-mercaptopurine (HD-6MP) during protocol M
Number of subjects: 467
Study: 10514950

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST-PC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7488410

Group type: EXPERIMENTAL
Intervention: EPI 120 mg/m2 every 3 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: EPI 120 mg/m2 + LND (150 mg on day 1, 300 mg on day 2, 450 mg on days 3-5)
Number of subjects: 45

Group type: COMPARATOR
Intervention: All patients
Number of subjects: 45
Study: 2139996

Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride aerosol therapy (10 mg/day on days 10, 12, 14, 16, 18, 20, 22)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Speleotherapy
Number of subjects: 40
Study: 7377255

Group type: EXPERIMENTAL
Intervention: 10 mg of estradiol valerate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31464912

Group type: EXPERIMENTAL
Intervention: SOCG (SOCG tablet)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 28716152

Group type: EXPERIMENTAL
Intervention: Implementation intervention consisting of 27 behaviour change techniques (BCTs)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Researcher panel opinion for BCT selection
Number of subjects: 76
Study: 25564797

Group type: EXPERIMENTAL
Intervention: PCL-based dermal filler
Number of subjects: 40

Group type: COMPARATOR
Intervention: NASHA-based dermal filler
Number of subjects: 40
Study: 24194293

Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV) 1,250 mg bid concurrent with temozolomide (TMZ) 150-200 mg/m(2) and radiotherapy (6,000 cGy)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV) 625 mg bid concurrent with temozolomide (TMZ) and radiotherapy
Number of subjects: 21
Study: 21992010

Group type: EXPERIMENTAL
Intervention: Neoprene wrist/hand splint
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Withdrawal of the splint
Number of subjects: 4
Study: 20810596

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics plus cognitive-behavioral therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Second-generation antipsychotics alone
Number of subjects: 33
Study: 17983301

Group type: EXPERIMENTAL
Intervention: Implicit self-esteem measures under threat conditions
Number of subjects: 4

Group type: COMPARATOR
Intervention: Self-affirmation intervention
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Threat manipulations
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Pretest anxiety
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ISEC among high-threat participants
Number of subjects: 4
Study: 15250203

Group type: EXPERIMENTAL
Intervention: Chuankezhi injection
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ginkgo injection
Number of subjects: 68
Study: 12431243

Group type: EXPERIMENTAL
Intervention: Oral taurine (1000 mg d(-1))
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 9836523

Group type: EXPERIMENTAL
Intervention: IDDM patients with a history of hypoglycemic coma
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: IDDM patients without a history of hypoglycemic coma
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: IDDM patients
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 108
Study: 8137333

Group type: COMPARATOR
Intervention: Daily supplementation with 26 vitamins and minerals for 6 years
Number of subjects: 3318

Group type: COMPARATOR
Intervention: Retinol and zinc supplementation
Number of subjects: 3318

Group type: COMPARATOR
Intervention: Beta-carotene, vitamin E, and selenium supplementation
Number of subjects: 3318
Study: 2680230

Group type: EXPERIMENTAL
Intervention: High carbohydrate meal
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High protein meal
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal (mixed) meal
Number of subjects: 7

Group type: COMPARATOR
Intervention: High fat meal
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 7
Study: 477258

Group type: EXPERIMENTAL
Intervention: Intravenous sodium chloride (50 mmol three times daily for 3 days)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intravenous sodium chloride (50 mmol in 50 ml over 22 min)
Number of subjects: 4
Study: 30447946

Group type: EXPERIMENTAL
Intervention: Packed RBCs greater than or equal to 22 days old
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Packed RBCs 0 to 7 days old
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Packed RBCs 8 to 14 days old
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Packed RBCs 15 to 21 days old
Number of subjects: 678
Study: 27480445

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 3110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 3110
Study: 26501788

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 23941366

Group type: EXPERIMENTAL
Intervention: Environmental exposures and gene-environment interactions
Number of subjects: 1400
Study: 21304064

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery (GB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lean subjects (L)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Obese subjects (O)
Number of subjects: 15
Study: 19809308

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 19225128

Group type: EXPERIMENTAL
Intervention: Milk/peanut FS
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Soy/peanut FS
Number of subjects: 1362

Group type: COMPARATOR
Intervention: CSB
Number of subjects: 1362
Study: 15262693

Group type: COMPARATOR
Intervention: MT‐1 (0.08 mg/kg per day subcutaneously) with UV‐B light (3 times the minimal erythema dose) for 10 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MT‐1 (0.16 mg/kg per day) with UV‐B radiation (0.25‐0.75 MED) for 10 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MT‐1 (0.16 mg/kg) for 5 days per week for 4 weeks with sunlight
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sunlight only
Number of subjects: 28
Study: 12596615

Group type: EXPERIMENTAL
Intervention: Body acupuncture during three consecutive days immediately before induction of ROD
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 40
Study: 9832091

Group type: EXPERIMENTAL
Intervention: Mitral annular calcium (MAC) group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (without MAC)
Number of subjects: 165
Study: 7807244

Group type: EXPERIMENTAL
Intervention: Teaching intervention on pressure ulcer risk, assessment, and treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control condition (no specific intervention details provided)
Number of subjects: 102
Study: 2642658

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 30
Study: 1251322

Group type: EXPERIMENTAL
Intervention: Vagotomy and drainage
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Vagotomy and hemigastrectomy
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy without drainage
Number of subjects: 157

Group type: COMPARATOR
Intervention: Simple closure
Number of subjects: 157
Study: 11229669

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 9014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study: 30832665

Group type: EXPERIMENTAL
Intervention: Health insurance card
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Medical treatment voucher
Number of subjects: 1919

Group type: COMPARATOR
Intervention: No health insurance
Number of subjects: 1919
Study: 30422784

Group type: EXPERIMENTAL
Intervention: DAD mobile BAI that included personalized feedback and interactive text messaging
Number of subjects: 84

Group type: COMPARATOR
Intervention: DAD information
Number of subjects: 84
Study: 27159290

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (20 mL Exparel + 20 mL 0.9% saline)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.25% bupivacaine hydrochloride (20 mL 0.5% bupivacaine HCl + 20 mL 0.9% saline)
Number of subjects: 32
Study: 24604894

Group type: EXPERIMENTAL
Intervention: Multisensory stimulation environment (MSSE) group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Individualized activities (activity) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 22850352

Group type: EXPERIMENTAL
Intervention: Tapentadol extended release (ER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxycodone controlled release (CR)
Number of subjects: 0
Study: 19432875

Group type: EXPERIMENTAL
Intervention: IOP-lowering intervention
Number of subjects: 10
Study: 16814935

Group type: EXPERIMENTAL
Intervention: Alcohol use during tobacco cessation treatment
Number of subjects: 101

Group type: COMPARATOR
Intervention: Pre-enrollment alcohol use
Number of subjects: 101
Study: 15701778

Group type: EXPERIMENTAL
Intervention: Flex-dose group (topiramate with adjustable AED cotherapy)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Fixed-dose group (topiramate with fixed AED cotherapy)
Number of subjects: 599
Study: 12213686

Group type: EXPERIMENTAL
Intervention: Mild-to-moderate depression
Number of subjects: 2558

Group type: EXPERIMENTAL
Intervention: Severe depressive syndromes
Number of subjects: 2558
Study: 9456212

Group type: EXPERIMENTAL
Intervention: Titration search procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ping-pong search procedure
Number of subjects: 0
Study: 8747898

Group type: EXPERIMENTAL
Intervention: Albumin (4.6%) + Plasmalyte (Group A, n = 32)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Polygeline (Hemaccel) + Plasmalyte (Group P, n = 29)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Crystalloid (Plasmalyte) alone (Group C, n = 32)
Number of subjects: 93
Study: 2709981

Group type: EXPERIMENTAL
Intervention: Lifting belt
Number of subjects: 9

Group type: COMPARATOR
Intervention: No lifting belt
Number of subjects: 9
Study: 938161

Group type: EXPERIMENTAL
Intervention: C3 treatment
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 213